Results 41 to 50 of about 684,663 (243)
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. [PDF]
, 2016 Immunomodulatory therapies, targeting the immune checkpoint receptor-ligand complex PD-1/PD-L1 have shown promising results in early phase clinical trials in solid malignancies, including carcinomas of the head and neck.
Pfarr, Nicole +19 more
core +1 more source
BMC Research Notes, 2020 Objective Programmed death-1 (PD-1) and its ligand PD-L1 are now used as predictive biomarkers to guide clinical decisions. Precise characterization of PD-L1-positive cells may contribute to our knowledge of which patients derive benefit from the PD-L1 ...
Markus Tiemann +3 more
doaj +1 more source
STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells
Cell Death and Disease, 2022 Immune checkpoint molecule programmed death-ligand 1 (PD-L1) is overexpressed in cancer cells and imparts resistance to cancer therapy. Although membrane PD-L1 has been targeted for cancer immune therapy, nuclear PD-L1 was reported to confer cancer ...
Je-Jung Lee +5 more
doaj +1 more source
Role of regulation of PD-1 and PD-L1 expression in sepsis
Frontiers in Immunology, 2023 Long term immunosuppression is problematic during sepsis. The PD-1 and PD-L1 immune checkpoint proteins have potent immunosuppressive functions. Recent studies have revealed several features of PD-1 and PD-L1 and their roles in sepsis. Here, we summarize
Teng Zhang, Li Yu-Jing, Tao Ma
doaj +1 more source
Identification of a Small Molecule that Binds to the PD-L1 Dimer Interface
, 2023 In recent years, antibody drugs targeting PD-1/PD-L1 immune checkpoints have shown immense clinical benefits in cancer treatment. However, these drugs suffer from poor patient tolerance, large and difficult-to-control adverse reactions, insufficient oral
Hengwei, Bian +5 more
core +1 more source
Deubiquitination and Stabilization of PD-L1 by CSN5 [PDF]
Cancer Cell, 2016 Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified tumor necrosis factor alpha (TNF-α) as a major factor triggering cancer cell immunosuppression against T cell surveillance via stabilization of programmed cell death-ligand 1 (
Seung-Oe, Lim +21 more
openaire +2 more sources
Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA [PDF]
, 2021 Hovedbudskap Programmed cell death ligand 1 (PD-L1) på tumorceller kan binde til Programmed cell death protein 1 på immunceller og hindre disse i å bekjempe og nøytralisere kreftsvulster.
Brurberg, Kjetil Gundro +2 more
core
, 2019 Figure S1. Anti-PD-L1 antibody exhibited in vivo activity on GV369-CON B-cell lymphoma. A and B: CD8+T cell percentage was enhanced, as well as CD8+T cell apoptosis and Fas expression were inhibited in GV369-CON group treated with anti-PD-L1 antibody.
Hui-Juan Zhong (799289) +9 more
core +1 more source
Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display
, 2022 Therapeutic monoclonal antibodies directed against PD-L1 (e.g., atezolizumab) disrupt PD-L1:PD-1 signaling and reactivate exhausted cytotoxic T-cells in the tumor compartment.
Brian J. Grindel (9407114) +10 more
core +1 more source
Histological evaluation of PD-L1 antibody in Head and Neck Squamous Cell Carcinomas (HNSCC)
, 2023 The thesis delves into the critical role of programmed death-ligand 1 (PD-L1) in Head and Neck Squamous Cell Carcinoma (HNSCC). PD-L1, a transmembrane protein found in tumor cells and immune cells, is expressed in higher amounts in specific cancer types,
Picanco Silva, Yasmin
core +1 more source